SCHEMBL2567338

SCHEMBL2567338

CCOC(=O)CSc1nc(-c2cc(OCOC)c(OC)cc2Cl)c2c(C#N)cn(COCC[Si](C)(C)C)c2n1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSP90AB1 P08238 10/20 0.47
HSP90AA1 P07900 3/20 0.46
KCNH2 Q12809 3/20 0.38
PIM1 P11309 1/20 0.35
ABCB1 P08183 1/20 0.34
TNF P01375 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
KDM4E B2RXH2 1/20 0.33
NPC1 O15118 1/20 0.33
USP2 O75604 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
NFKB1 P19838 1/20 0.33
CASP1 P29466 1/20 0.33
RAB9A P51151 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3956701 0.92 HSP90AB1 (0.48) HSP90AB1HSP90AA1KCNH2
SCHEMBL3956211 0.92 HSP90AB1 (0.47) HSP90AB1HSP90AA1KCNH2PIM1ABCB1
SCHEMBL3956064 0.91 HSP90AA1 (0.57) HSP90AB1HSP90AA1KCNH2SMN1; SMN2
SCHEMBL4134884 0.91 HSP90AB1 (0.50) HSP90AB1HSP90AA1KCNH2PIM1ABCB1
SCHEMBL3961424 0.89 HSP90AB1 (0.42) HSP90AB1HSP90AA1KCNH2TNFNPC1
SCHEMBL2562416 0.87 HSP90AB1 (0.46) HSP90AB1HSP90AA1KCNH2
SCHEMBL2564620 0.86 HSP90AB1 (0.55) HSP90AB1HSP90AA1KCNH2PIM1
SCHEMBL3955735 0.86 HSP90AA1 (0.62) HSP90AB1HSP90AA1KCNH2SMN1; SMN2
SCHEMBL3961421 0.85 HSP90AB1 (0.40) HSP90AB1HSP90AA1KCNH2TNFL3MBTL1
SCHEMBL2568885 0.85 HSP90AB1 (0.48) HSP90AB1HSP90AA1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2007767-B1 PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS VERNALIS R&D LTD (GB) 2011-11-02 EP disclosed
US-20090163490-A1 Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors VERNALIS (R&D) LTD. (GB) 2009-06-25 US disclosed
US-20090163490-A1 Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors VERNALIS (R&D) LTD. (GB) 2009-06-25 US disclosed
WO-2009030871-A1 PYRROLOPYRIMIDINE DERIVATIVES HAVING HSP90 INHIBITORY ACTIVITY VERNALIS R & D LTD (GB) 2009-03-12 WO disclosed
EP-2007767-A1 PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS VERNALIS (R&D) LTD (GB) 2008-12-31 EP disclosed
WO-2007104944-A1 PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS VERNALIS (R & D) LTD. (GB) 2007-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163490-A1 Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors HSP90AA1, HSP90AB1, RAF1 HSP90AB1 2/4885HSP90AA1 1/4885KCNH2 2202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.